Sarah Pett
   HOME

TheInfoList



OR:

Sarah L. Pett is a Professor of Infectious Diseases at
University College London University College London (Trade name, branded as UCL) is a Public university, public research university in London, England. It is a Member institutions of the University of London, member institution of the Federal university, federal Uni ...
. Pett is interested in the
immunopathology Immunopathology is a branch of medicine that deals with immune responses associated with disease. It includes the study of the pathology of an organism, organ system, or disease with respect to the immune system, immunity, and immune responses. In ...
of infections and the development of optimised treatment pathways for infections. During the
COVID-19 pandemic The COVID-19 pandemic (also known as the coronavirus pandemic and COVID pandemic), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began with an disease outbreak, outbreak of COVID-19 in Wuhan, China, in December ...
, Pett led a clinical trial that investigated the efficacy of
remdesivir Remdesivir, sold under the brand name Veklury, Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. is a Broad-spectrum antiviral drug, broad-spectrum ...
as a treatment for
coronavirus disease Coronavirus diseases are caused by viruses in the coronavirus subfamily, a group of related RNA viruses that cause diseases in mammals and birds. In humans and birds, the group of viruses cause respiratory tract infections that can range from ...
.


Research and career

In 2000 Pett joined the Kirby Institute in
New South Wales New South Wales (commonly abbreviated as NSW) is a States and territories of Australia, state on the Eastern states of Australia, east coast of :Australia. It borders Queensland to the north, Victoria (state), Victoria to the south, and South ...
, where she led international
randomized controlled trials A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical ...
. In 2013 Pett joined the Medical Research Council Clinical Trials Unit at
University College London University College London (Trade name, branded as UCL) is a Public university, public research university in London, England. It is a Member institutions of the University of London, member institution of the Federal university, federal Uni ...
. She was promoted to the Chair of the Infectious Diseases theme in 2016. During the
COVID-19 pandemic The COVID-19 pandemic (also known as the coronavirus pandemic and COVID pandemic), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began with an disease outbreak, outbreak of COVID-19 in Wuhan, China, in December ...
Pett led the Adaptive COVID-19 Treatment Trial (ACTT-EU/UK), a clinical trial into the efficacy of
remdesivir Remdesivir, sold under the brand name Veklury, Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. is a Broad-spectrum antiviral drug, broad-spectrum ...
as a treatment from
coronavirus disease Coronavirus diseases are caused by viruses in the coronavirus subfamily, a group of related RNA viruses that cause diseases in mammals and birds. In humans and birds, the group of viruses cause respiratory tract infections that can range from ...
. Adult inpatients were given
remdesivir Remdesivir, sold under the brand name Veklury, Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. is a Broad-spectrum antiviral drug, broad-spectrum ...
or a placebo through a drip for up to ten days of their stay in hospital. Pett showed that patients treated with
remdesivir Remdesivir, sold under the brand name Veklury, Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. is a Broad-spectrum antiviral drug, broad-spectrum ...
recovered 31% faster than those who did not receive treatment. She has also been involved in research on the neurological complications from COVID-19 and the co-morbid conditions that it may induce.


Selected publications

* * *


References

{{DEFAULTSORT:Pett, Sarah Living people Year of birth missing (living people) Alumni of the University of Edinburgh COVID-19 researchers Academics of University College London British medical researchers Medical Research Council (United Kingdom) people British women medical researchers 21st-century women scientists